September 2023 in “Journal of the American Academy of Dermatology” Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2023 in “Journal of the American Academy of Dermatology” 
March 2026 in “The American Journal of Managed Care” The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.
This source provides medical information intended solely for licensed professionals and emphasizes that it is not a substitute for medical advice, diagnosis, or treatment decisions, which remain the responsibility of treating physicians.